Endothelium, venous thromboembolism and ischaemic cardiovascular events

Paolo Gresele; Stefania Momi; Rino Migliacci

doi:10.1160/TH09-08-0562

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 103(01): 56-61
DOI: 10.1160/TH09-08-0562

Review Article

Schattauer GmbH

Endothelium, venous thromboembolism and ischaemic cardiovascular events

Authors

Paolo Gresele

¹Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Italy
Stefania Momi

¹Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Italy
Rino Migliacci

²Division of Internal Medicine, Ospedale della Valdichiana “S.Margherita”, Cortona, Italy

Abstract

Summary

The association between venous thromboembolism and arterial thrombosis has emerged as consistent clinical observation in the last few years. While several experimental, epidemiological and pharmacologic studies support this association, the initial pathophysiological mechanism linking these two clinical conditions remains to be established. This review discusses the pathophysiological bases and a number of experimental and clinical observations suggesting that the common link between venous thromboembolism and arterial thrombosis is represented by a dysfunctional endothelium.

Keywords

Arterial thrombosis - atherothrombosis - venous thrombosis - endothelial cells - nitric oxide/NO

Volltext

Referenzen

References
1 Prandoni P, Bilora F, Marchiori A. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
2 Sorensen HT, Horvath-Puho E, Pedersen L. et al. Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events: a 20-year Cohort Study. Lancet 2007; 370: 1773-1779.
3 Becattini C, Agnelli G, Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83.
4 Ray JG, Mandani M, Tsuyuki T. et al. Use of statins and the subsequent development of deep venous thrombosis. Arch Intern Med 2001; 161: 1405-1410.
5 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
6 Lowe GDO. Common risk factors for both arterial and venous thrombosis. Brit J Haematol 2008; 140: 488-495.
7 Goldhaber SZ, Grodstein F, Stampfer MJ. et al. A prospective study of risk factors for pulmonary embolism in women. J Am Med Assoc 1997; 277: 642-645.
8 Petrauskiene V, Falk M, Waernbaum I. et al. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005; 48: 1017-1021.
9 Stein PD, Goldman J, Matta F. et al. Diabetes mellitus and risk of venous thromboembolism. Am J Med Sci 2009; 337: 259-264.
10 Ageno W, Becattini C, Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
11 Severinsen MT, Kristensen SR, Johnsen SP. et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 07: 1297-1303.
12 Jang MJ, Choi WI, Bang SM. et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol 2009; 29: 311-315.
13 Sofi F, Marcucci R, Abbate R. et al. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007; 120: 728-733.
14 Braekkan SK, Mathiesen EB, Njølstad I. et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost 2008; 06: 1851-1857.
15 Wattanakit K, Cushman M, Stehman-Breen C. et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19: 135-140.
16 Mahmoodi BK, Gansevoort RT, Veeger NJ. et al. Microalbuminuria and risk of venous thromboembolism. J Am Med Assoc 2009; 301: 1790-1797.
17 Foslom AR, Lutsey L, Astor BC. et al. C-reactive protein and venous thromboembolism: a prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-619.
18 Eichinger S, Stümpflen A, Hirschl M. et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569.
19 Matta F, Singala R, Yaekoub AY. et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
20 Smeet L, Cook C, Thomas S. et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.
21 Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008; 336: 402-406.
22 Baccarelli A, Martinelli I, Zanobetti A. et al. Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med 2008; 168: 920-927.
23 Bennet PC, Silverman SH, Gill PS. et al. Peripheral arterial disease and Virchow’s triad. Thromb Haemost 2009; 101: 1032-1040.
24 Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Testing and clinical relevance. Circulation 2007; 115: 1285-1295.
25 Raiesdana A, Loscalzo J. Vessel wall-derived substances affecting platelets. In: Platelets in Hematological and Cardiovascular Disorders. A Clinical Handbook. Cambridge University Press; 2008: 92-105.
26 Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-549.
27 Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387-391.
28 Takahashi M, Yamashita A, Moriguchi-Goto S. et al. Critical role of von Wille-brand factor and platelet interaction in venous thromboembolism. Histol Histopathol 2009; 24: 1391-1398.
29 Del Conde I, Lòpez JA. Classification of venous thromboembolism (VTE). J Thromb Haemost 2005; 03: 2573-2575.
30 Sessa C, Morasch MD, Friedland M. et al. Risk factors of atherosclerosis and safenous vein endothelial function. Int Angiol 2001; 20: 152-163.
31 Momin A, Melekian N, Wheatcroft SB. et al. The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 134: 335-341.
32 Pang CCY. Measurement of body venous tone. J Pharmacol Toxicol Metods 2000; 44: 341-360.
33 Vallance P, Collier J, Moncada S. Nitric oxide synthesized from L-arginine mediates endothelium-dependent venodilatation in human hand veins in vivo. Cardiovasc Res 1989; 23: 1053-1057.
34 Blackman DJ, Morris-Thurgood JA, Atherton JJ. et al. Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans. Circulation 2000; 101: 165-170.
35 Shantsila E, Lip GYH. The endothelium and thrombotic risk in heart failure. Thromb Haemost 2009; 102: 185-187.
36 Rubira MC, Consolim Colombo FM, Rabelo ER. et al. Venous or arterial endothelium evaluation for early cardiovascular dysfunction in hypertensive patients ?. J Clin Hypertens 2007; 09: 859-865.
37 Moreno H, Chalon S, Urae A. et al. Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. Am J Physiol 1998; 44: H1040-1045.
38 Rabelo ER, Ruschel K, Moreno Jr, H. et al. Venous endothelial function in heart failure: comparison with healthy controls and effect of clinical compensation. Eur J Heart Fail 2008; 10: 758-764.
39 Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-argi-nine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53: 1068-1077.
40 Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
41 Rakici O, Kiziltepe U, Coskun B. et al. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol 2005; 105: 209-215.
42 Al-Benna S, Hamilton CA, McCore JD. et al. Low-density lipoprotein cholesterol determines oxidative stress and endothelial dysfunction in saphenous veins from patients with coronary artery disease. Arterioscler Thrombos Vasc Biol 2005; 26: 218-223.
43 Smeet L, Thomas SL, All AJ. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-2618.
44 Hingorani AD, Cross J, Kharbanda RK. et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999.
45 Rectenwald GE, Myers DD, Hawley AE. et al. D-dimer, P-selectin and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost 2005; 94: 1312-1317.
46 Nozaki T, Sugiyama S, Koga H. et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54: 601-608.
47 Burnier L, Fontana P, Kwak BR. et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
48 Pecheniuk NM, Elias DJ, Deguchi H. et al. Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost 2008; 100: 224-228.
49 Yoshida A, Nakao S, Kobayashi M. et al. Flow-mediated vasodilation and plasma fibronectin levels in preeclampsia. Hypertension 2000; 36: 400-404.
50 Brook RD, Brook JR, Urch B. et al. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation 2002; 105: 1534-1536.
51 Gaeta G, De Michele M, Cuomo S. et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343: 840-846.
52 Clausen P, Jensen JS, Jensen G. et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103: 1869.
53 Migliacci R, Becattini C, Pesavento R. et al. Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 2007; 92: 812-818.
54 Gresele P, Migliacci R, Vedovati MC. et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009; 123: 444-451.
55 Ridker PM, Danielson E, Fonseca FAH. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med 2008; 359: 2195-2207.
56 Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-736.
57 Vita JA, Keaney JF, Larson MG. et al. Brachial artery vasodilator function and systemic inflammation in the Framingham offspring study. Circulation 2004; 110: 3604-3609.
58 Bergan JJ, Schmid-Schonbein GW, Coleridge Smith PD. et al. Chronic venous disease. N Engl J Med 2006; 355: 488-498.
59 Kanai AJ, Strauss HC, Truskey GA. et al. Shear stress induces ATP-independent transient nitric oxide release from vascular endothelial cells, measured directly with a porphyrinic microsensor. Circ Res 1995; 77: 284-293.
60 Myers RJ, Alevriadov BR, McIntire LV. Rheology. In: Thrombosis and Haemorrhage. 2^nd edition Williams & Wilkins; 1998. pp. 405-494.
61 De Sousa MG, Yugar-Toledo JC, Rubira M. et al. Ascorbic acid improves impaired venous and arterial endothelium-dependent dilation in smokers. Acta Pharmacol Sin 2005; 26: 447-452.